This websites is for informational and educational purposes only. We do not sell Asthalin inhaler, tablets, respules, syrup or any other medicinal product.

Background

Salbutamol, widely known as albuterol or by the brand name Asthalin, was synthesized in 1966 by a British research team led by pharmacist Sir David Jack at Allen & Hanburys. Developed by modifying the chemical structure of adrenaline to improve receptor selectivity, it was designed as a safer alternative to older, non-selective asthma treatments like isoprenaline, which carried dangerous cardiovascular risks. Launched commercially in 1969, it revolutionized respiratory medicine by becoming the world's first selective beta-2 adrenergic receptor agonist. This selective targeting allowed it to successfully relax bronchial smooth muscles and rapidly alleviate asthma attacks while causing minimal side effects to the heart. Over half a century later, salbutamol remains on the World Health Organization's List of Essential Medicines and stands as the most widely prescribed "rescue" bronchodilator for managing asthma and chronic obstructive pulmonary disease (COPD) across the globe.

Medical Uses

Asthalin is classified as a "reliever" or "rescue" medication rather than a preventer. It is used for:

- The relief of acute bronchospasm associated with asthma attacks, including wheezing, shortness of breath, chest tightness, and coughing.

- Prevention of exercise-induced or allergen-induced bronchospasm, when taken 10–15 minutes before exposure to the trigger.

- Symptomatic management of chronic obstructive pulmonary disease (COPD).

- As part of chronic maintenance therapy for reversible airways obstruction, typically alongside inhaled corticosteroids for patients with persistent asthma.

Salbutamol acts selectively on beta-2 adrenergic receptors in bronchial smooth muscle, causing relaxation of the airway walls and widening of the bronchial passages, which allows easier airflow into/out of the lungs. It has little effect on beta-1 receptors in cardiac tissue at therapeutic doses, though cardiac side effects can still occur.

Dosage

Dosage varies by age, formulation, and clinical indication, and should be determined by a physician. Representative adult dosing for the inhaler, per manufacturer and regulatory labeling, is as follows:

- Acute symptom relief: One inhalation (100 mcg) as a starting dose, increased to two inhalations if necessary.

- Prevention of exercise- or allergen-induced symptoms: Two inhalations 10–15 minutes before exposure.

- Chronic therapy: Two inhalations up to four times daily.

- Maximum recommended dose: Not exceeding 8 inhalations in 24 hours, with doses generally spaced at least 4 hours apart.

Pediatric dosing is generally lower and adjusted by age and body weight. Patients requiring increasingly frequent use of Asthalin are advised to seek medical review, as this can indicate deteriorating asthma control.

Contraindications

Asthalin is contraindicated in individuals with known hypersensitivity to salbutamol or any of its excipients. Non-intravenous salbutamol formulations, including Asthalin, are contraindicated for arresting uncomplicated premature labour or threatened abortion.
It should be used with caution in patients with thyrotoxicosis, coronary insufficiency, hypertrophic obstructive cardiomyopathy, arterial hypertension, tachyarrhythmias, or diabetes mellitus, and in those taking cardiac glycosides.

Side Effects

Asthalin is generally well tolerated at recommended doses, and most adverse effects are mild and transient.

Common side effects include fine tremor (particularly of the hands), headache, dizziness, tachycardia (rapid heartbeat), and a sense of tenseness or nervousness.

Less common effects include palpitations, throat or mouth irritation, muscle cramps, and myalgia.

Rare side effects include hypokalaemia (low blood potassium, particularly when combined with corticosteroids, diuretics, or xanthine derivatives), peripheral vasodilation, sleep disturbances, hallucinations (particularly in children), nausea, vomiting, and dry mouth.

Very rare but serious effects include hypersensitivity reactions such as angioedema, urticaria, hypotension, and paradoxical bronchospasm (a sudden worsening of wheezing immediately after use, which requires discontinuation of the drug). Cardiac arrhythmias, including atrial fibrillation, have also been reported very rarely, particularly with concomitant use of other beta-2 agonists.

Overdose can produce exaggerated versions of the above effects, including hypokalaemia, hyperglycaemia, agitation, and, in severe cases, lactic acidosis.

Drug Interactions

Salbutamol should generally not be co-administered with non-selective beta-blockers such as propranolol, as these can antagonize its bronchodilator effect. Monoamine oxidase inhibitors, tricyclic antidepressants, and digoxin may increase the risk of cardiovascular side effects. Concomitant use with xanthines, corticosteroids, diuretics, or long-term laxatives may worsen salbutamol-induced hypokalaemia. Patients are typically advised to discontinue salbutamol at least six hours before elective anaesthesia involving halogenated anaesthetics, where possible.

Pregnancy & Breastfeeding

Salbutamol has been in widespread clinical use during pregnancy for decades without strong evidence of harm at standard inhaled doses, though formal controlled trials in pregnant women are lacking. It is generally used in pregnancy only when the expected benefit to the mother is judged to outweigh potential risk to the fetus. Salbutamol is thought to pass into breast milk in small amounts, and caution is advised in nursing mothers.

Pharmacology

Salbutamol is a sympathomimetic amine that acts as a selective agonist at beta-2 adrenergic receptors, predominantly located in bronchial smooth muscle. Stimulation of these receptors activates adenylate cyclase, increasing intracellular cyclic AMP, which in turn relaxes bronchial smooth muscle and produces bronchodilation.

After inhalation, roughly 10–20% of the delivered dose reaches the lower airways, with the remainder largely deposited in the oropharynx and swallowed. The swallowed fraction undergoes significant first-pass hepatic metabolism. Salbutamol is approximately 10% bound to plasma proteins and is eliminated primarily via the kidneys, both as unchanged drug and as an inactive phenolic sulfate metabolite. Following intravenous administration, its elimination half-life is approximately 4 to 6 hours.

Manufacturer & Market Presence

Asthalin is produced by Cipla Limited, headquartered in Mumbai, India, one of the world's largest generic pharmaceutical manufacturers. Cipla markets salbutamol under the Asthalin brand primarily in India and other markets across Asia, Africa, and the Middle East, while a corresponding Cipla-manufactured salbutamol inhaler is sold in parts of Europe (including the United Kingdom) under the same Asthalin name. In many other countries, salbutamol/albuterol equivalent products are marketed under different brand names, such as Ventolin (GlaxoSmithKline) and ProAir or Proventil (in the United States).